Health systems are increasingly the source of scientific innovation that not only leads to new treatments for diseases but also the commercialization activity and funding for biotech startups.
This panel of health system investment leaders from Johns Hopkins, Mass General Brigham, and UPMC discusses how and why their organizations are taking an active role in funding innovation and commercialization in life sciences. The experts also discuss how their strategies differ from traditional venture investors.
Moderated by an experienced venture capitalist from Lightstone Ventures, the panel addresses:
- How proximity to clinicians and researchers can catalyze the identification and acceleration of the most impactful ideas.
- Which intangible assets and value health system investors can bring to bear.
- How they can bridge early-stage funding.
- Partnerships that can accelerate discoveries from bench to bedside.
Based on the latest research report from the Center for Connected Medicine, “A New Player in Biotech Investing,” which identifies 15 health systems leading in company formation and venture investing, the panel delivers insights on a vital new player in the creation of therapies.